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A B S T R A C T
Background. Phosphate (Pi) toxicity is a strong determinant of
vascular calcification development in chronic kidney disease
(CKD). Magnesium (Mg2þ) may improve cardiovascular risk
via vascular calcification. The mechanism by which Mg2þ coun-
teracts vascular calcification remains incompletely described.
Here we investigated the effects of Mg2þ on Pi and secondary
crystalline calciprotein particles (CPP2)-induced calcification
and crystal maturation.
Methods. Vascular smooth muscle cells (VSMCs) were treated
with high Pi or CPP2 and supplemented with Mg2þ to study
cellular calcification. The effect of Mg2þ on CPP maturation,
morphology and composition was studied by medium absor-
bance, electron microscopy and energy dispersive spectroscopy.
To translate our findings to CKD patients, the effects of Mg2þ
on calcification propensity (T50) were measured in sera from
CKD patients and healthy controls.
Results. Mg2þ supplementation prevented Pi-induced calcifica-
tion in VSMCs. Mg2þ dose-dependently delayed the matura-
tion of primary CPP1 to CPP2 in vitro. Mg2þ did not prevent
calcification and associated gene and protein expression when
added to already formed CPP2. Confirmatory experiments in
human serum demonstrated that the addition of 0.2 mmol/L
Mg2þ increased T50 from healthy controls by 51 6 15 min
(P< 0.05) and CKD patients by 44 6 13 min (P< 0.05). Each
further 0.2 mmol/L addition of Mg2þ led to further increases in
both groups.
Conclusions. Our results demonstrate that crystalline CPP2
mediates Pi-induced calcification in VSMCs. In vitro, Mg2þ
delays crystalline CPP2 formation and thereby prevents Pi-
induced calcification.
Keywords: calciprotein particle, calcification propensity,
chronic kidney disease, magnesium, vascular calcification
I N T R O D U C T I O N
Vascular calcification contributes to cardiovascular morbidity
and mortality in chronic kidney disease (CKD) [1]. Currently
treatment options are limited and persisting vascular calcifica-
tion remains a clinical problem. In past years, several epidemio-
logical studies have shown that a lower serum magnesium
(Mg2þ) status is independently associated with an increased
risk of vascular calcification and cardiovascular mortality in
CKD patients [2–4]. Therefore it is hypothesized that Mg2þ
could be an effective tool to limit vascular calcification [5].
However, the mechanisms underlying the potent anti-
calcification properties of Mg2þ are incompletely understood.
Hydroxyapatite- and protein-containing calciprotein par-
ticles (CPPs) are major drivers of calcification [6, 7]. The transi-
tion from calcium (Ca2þ)- and phosphate (Pi)-containing
amorphous or primary CPP1 towards crystalline or secondary
CPP2 is key in the development of vascular smooth muscle cell
(VSMC) calcification [6, 8]. Due to disturbances in the bone–
mineral axis, resulting from in elevated Pi and decreased calcifi-
cation inhibitors such as matrix gla protein (MGP) and fetuin-
A, high Pi levels crystallize into CPP2 [7, 9]. These events result
in active reprogramming of VSMCs, which in turn enhances
the calcification process by up-regulating osteogenic genes, pro-
ducing excess extracellular matrix, undergoing apoptosis and
releasing pro-calcific exosomes [10–12].
Since VSMCs may activate osteogenic pathways that con-
tribute to calcification, the capacity of Mg2þ to inhibit vascular
calcification may rely on direct modulation of these cellular
processes [13]. Indeed, multiple studies demonstrate that Mg2þ
did not inhibit calcification upon transient receptor potential
melastatin 7 blocking, an abundant Mg2þ channel in VSMCs,
implying that intracellular Mg2þ prevents calcification [14, 15].
In addition, Mg2þ supplementation in vitro correlates with
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reduced expression of pro-calcification genes and with in-
creased expression of calcification protectors [16–18]. On the
contrary, in the extracellular compartment, Mg2þ has potent
anti-crystallization properties, which have been shown to be of
importance in its capacity to prevent VSMC calcification
in vitro [19–22].
The importance of CPP2 in the development of vascular cal-
cification has been exploited in a novel diagnostic tool where
the intrinsic capacity of patient serum to prevent the transition
from CPP1 to CPP2, or calcification propensity of the serum,
can be measured using the T50 test [7, 23, 24]. The identification
of factors affecting T50 is of interest in the context of clinical
management of vascular calcification, as these factors may in-
fluence the development and progression of vascular calcifica-
tion in renal disease patients [23, 25–27]. T50 is correlated with
cardiovascular mortality and is affected by Pi [23]. Therefore,
whether Pi toxicity resulting in increased risk for vascular calci-
fication is determined by the presence of soluble Pi or that Pi
toxicity is mediated by crystallization in CPP2 is important to
consider.
In this study we aimed to delineate the mechanisms that ex-
plain the effects of Mg2þ on VSMC calcification. In our study
we induced VSMC calcification using both Pi and CPP2, which
allows comparison of the direct and indirect effects of Mg2þ
supplementation on VSMC calcification. Using scanning elec-
tron microscopy (SEM) and energy dispersive spectroscopy
(EDX), we studied CPP transition, morphology and composi-
tion in the presence and absence of Mg2þ in vitro. Furthermore,
we studied the influence of Mg2þ on calcification propensity in
serum from CKD patients and healthy controls ex vivo.
M A T E R I A L S A N D M E T H O D S
Cell culture
Human aortic VSMCs (hVSMCs) were purchased from the
American Type Culture Collection (Manassas, VA, USA, lot
no. PCS-100-012) and cultured in Dulbecco’s Modified Eagle
Medium (DMEM; Lonza, Basel, Switzerland) consisting of 20%
(v/v) foetal bovine serum (FBS; BioWest, GE Healthcare, Little
Chalfont, UK), 2 mmol/L L-glutamine and 10 lg/mL ciproflox-
acin at 37C in a humidified incubator containing 5% carbon
dioxide (CO2; v/v). Cells were used until the 10th passage. For
calcification experiments, cells were cultured in 12-well plates
and switched to calcification medium at subconfluence.
Calcification medium consisted of 5% FBS (v/v) and 3 mmol/L
Pi (NaH2PO4), and 2 mmol/L Mg
2þ when indicated. Cells were
cultured for up to 8 days. The medium was changed every 2–
3 days.
CPP synthesis, isolation and induction of calcification
Phenol red-free DMEM (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) was supplemented with 3.5 mmol/L
NaH2PO4, 1 mmol/L calcium chloride, 10% FBS (v/v), 2 mmol/
L L-glutamine and 10 lg/mL ciprofloxacin and stored in a hu-
midified incubator at 37C containing 5% CO2 (v/v) for
14 days. For isolation of CPP2, CPP-containing media were
centrifuged at 16 000 g for 30 min at room temperature. The
pellet was resuspended in DMEM containing 10 lg/mL cipro-
floxacin and stored at 4C. The Ca2þ content of the CPP2 sus-
pension was measured using the o-cresolphthalein complexone
method as described elsewhere [19]. Cells were treated with
CPP2 at a final concentration ranging from 5 to 100 lg/mL
Ca2þ (5–100 CPP). Cells were cultured in their designated me-
dia for up to 4 days without a change of media.
Analysis of VSMC calcification
Quantification of total cellular Ca2þ deposition using the o-
cresolphthalein complexone method and alizarin red staining
were performed as previously described [19].
Gene expression analysis
Total RNA was isolated from hVSMCs using TRIzol
(Invitrogen, Thermo Fisher Scientific) according to the manu-
facturer’s instructions. Genomic DNA was removed by DNAse
treatment prior to omplementary DNA synthesis from 1 lg to-
tal RNA (Promega, Madison, WI, USA). The primers used for
polymerase chain reaction (PCR) amplification were equally ef-
ficient (Supplementary data, Table S1). Reverse transcription
quantitative PCR was executed in duplicate using IQ
SYBRGreen Mix (Bio-Rad, Hercules, CA, USA) according to
the manufacturer’s protocol in a Bio-Rad thermocycler. The ex-
pression levels of genes of interest were normalized to GAPDH
expression levels.
Protein expression analysis
To prepare total lysate of hVSMCs, the hVSMC monolayer
was scraped in a 1% (v/v) Triton-X100 lysis buffer containing
protease inhibitors. The protein concentration was determined
using the Pierce BCA Kit according to the manufacturer’s
instructions (Thermo Fisher Scientific Waltham). Subsequently
samples consisting of equal amounts of protein were denatured
in Laemmli buffer containing 10 mmol/L dithiothreitol and ap-
plied to sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis. Blots were incubated at 4C overnight with primary
antibodies against osteopontin (OPN; 1:1000; R&D Systems,
Minneapolis, MN, USA; #MAB14331-100), transgelin (SM22a;
1:5000; Abcam, Cambridge, UK; #ab14106) and MGP (1:500;
Proteintech, Rosemont, IL; #10734-1-AP). Blots were subse-
quently incubated with horseradish peroxidase conjugated sec-
ondary antibodies for 1 h at room temperature. Band intensity
was measured using ImageJ software (National Institutes of
Health, Bethesda, MD, USA) and expression was corrected for
b-actin and expression levels per group were normalized to the
control.
Electron microscopy
CPPs were transferred onto copper tape, coated with carbon
and used for SEM analysis (GeminiSEM, Zeiss, Oberkochen,
Germany) and EDX for elemental analysis (QUANTAX 200,
Bruker, Billerica, MA, USA). Images were obtained using an
Everhart–Thornley secondary electron detector (Bruker) at
5 kV for morphological observations and 20 kV for microele-
mental analyses. For transmission EM (TEM), the CPP solution
was transferred onto a Formvar-coated copper grid and air
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dried. TEM was performed on a JEOL JEM 1400 microscope
(JEOL USA, Peabody, MA, USA) with an accelerating voltage
of 60 kV. Images were acquired at 15 000-fold magnification
(Gatan, Pleasanton, CA, USA).
CPP maturation assay
CPP2 were generated in phenol red-free DMEM (Gibco)
containing 10% FBS and MgCl2 was added to reach 1.0, 1.2, 1.4,
1.6, 1.8 and 2.0 mmol/L. As a reference, medium containing
10% FBS (v/v) was included. CPP2 maturation was monitored
by daily measurement of the absorption at 570 nm for 14 days
using a Benchmark Plus Microplate Spectrophotometer System
(Bio-Rad) [6]. A separate group where MgCl2 was added only
after absorption exceeded 0.15 (after 5 days) was included to
study the effects of Mg2þ on already formed CPP2 and moni-
tored until complete ripening after 14 days. To study the effects
of high Pi on the inhibition of CPP2 by 2.0 mmol/L Mg2þ,
CPP2 maturation was monitored in the presence of 4 and
5 mmol/L Pi (final concentration) in addition to the standard
CPP mixture in a separate experiment. To test a potential role
for Mg2þ in altering the pH of the CPP mixtures, pH was mea-
sured for the CPP mixtures without Mg2þ and with 2.0 mmol/L
Mg2þ at 0, 7 and 14 days of incubation.
Calcification propensity (T50 test) in serum samples
supplemented with Mg2þ
Serum samples collected prior to transplantation from renal
transplant recipients (CKD patients) and donors (healthy con-
trols) of the TransplantLines cohort study (METc UMCG No.
2014/077, NTC03272841) were used in this study [28]. Blood
from 10 subjects per group was collected in 4 mL serum collec-
tion tubes and centrifuged at 1300 g for 10 min at room temper-
ature. Serum was stored at 80C until analysis. The T50 test
(calcification propensity) has been described previously [24].
Serum was subjected to the T50 test without any additions
(baseline) and after addition of solutions with MgCl2 resulting
in increased concentrations of 0.2, 0.4, 0.6, 0.8 and 1.0 mmol/L.
After 570 min, the test was terminated. Other laboratory meas-
urements were performed during routine clinical visits prior to
serum collection for this study (Supplementary data, Table S2).
Statistical analysis
Parametric data were analysed by one-way analysis of vari-
ance (ANOVA) with Tukey’s post hoc test to correct for multi-
ple comparisons using PRISM software (GraphPad Software,
San Diego, CA, USA). Non-parametric data as identified by the
Shapiro–Wilk test for normality were analysed using Kruskal–
Wallis analysis with Dunn’s correction for multiple compari-
sons. For grouped analysis, data were analysed using a two-way
ANOVA. All data are shown as mean 6 standard deviation
(SD). P-values<0.05 were considered statistically significant.
R E S U L T S
Mg2þ prevents high Pi–induced VSMC calcification
To study the preventive effect of Mg2þ on in vitro calcifica-
tion, VSMCs were cultured in Pi medium and supplemented
with MgCl2 (Figure 1). VSMCs cultured in high Pi showed cal-
cification, as visualized by the alizarin red staining (Figure 1A)
and as quantified by the o-cresolphthalein complexone method
for Ca2þ (Figure 1B). VSMCs cultured in high Pi supplemented
with Mg2þ stained negative for alizarin red and Ca2þ deposition
was reduced by >100-fold versus high Pi–treated VSMCs after
8 days (28 6 12 versus 2990 6 1800 lg Ca2þ/mg protein;
P< 0.05). The preventive effect of Mg2þ on hVSMC calcifica-
tion was preserved at 4 and 5 mmol/L Pi (Supplementary data,
Figure S1). To evaluate the effect of Mg2þ on genetic changes
induced by calcification in VSMCs, the gene expression of calci-
fication inducers alkaline phosphatase (ALP) and OPN and cal-
cification inhibitor MGP in addition to contractile markers
calponin (CNN1) and SM22a were studied (Figure 1C).
Compared with control VSMCs, VSMCs cultured in 3 mmol/L
Pi had a 40–60% reduction in ALP and SM22a gene expression
after both 6 and 8 days of incubation (P< 0.05). MGP mRNA
expression remained stable. After high Pi treatment for 8 days,
VSMCs expressed only 20% of CNN1 gene expression com-
pared with control VSMCs (P< 0.05). Pi-treated VSMCs did
not change OPN gene expression. Mg2þ supplementation in ad-
dition to high Pi preserved the levels of MGP, ALP, SM22a and
CNN1 gene expression versus control VSMCs. VSMCs treated
with 2 mmol/L Mg2þ alone and in combination with 3 mmol/L
Pi showed a non-significant downregulation of OPN after
8 days. On a protein level, OPN was increased 2-fold by Pi treat-
ment (P< 0.05). Furthermore, SM22a protein expression was
decreased after 8 days of Pi treatment. In high Pi–treated
hVSMCs supplemented with Mg2þ, both the increased OPN
and decreased SM22a protein expression were normalized.
MGP protein expression remained stable in all treatment
groups (Figure 1D).
CPPs induce VSMC calcification independent of Mg2þ
To be able to distinguish between intracellular and extracel-
lular actions of Mg2þ, the effects of Mg2þ on CPP2-induced
VSMC calcification were assessed (Figure 2). Alizarin red stain-
ing (Figure 2A) and Ca2þ deposition measurements (Figure 2B)
showed increased calcification after 24 h in VSMCs treated with
50 CPP2 (488 6 62 versus 2 6 2 lg Ca2þ/mg protein;
P< 0.05). Mg2þ supplementation to CPP2-treated VSMCs did
not reduce Ca2þ deposition compared with CPP2-only treated
VSMCs after 24 h (488 6 62 versus 565 6 62 lg Ca2þ/mg pro-
tein) and 4 days (657 6 132 versus 783 6 142 lg Ca2þ/mg pro-
tein, respectively). CPP2 treatment decreased CNN1 gene
expression by almost 50% after both 2 days and 4 days
(Figure 2C; P< 0.05). CPP2 treatment resulted in downregula-
tion of OPN and ALP after 2 days, which seemed to be pre-
vented by Mg2þ. SM22a mRNA expression was decreased after
2 days of CPP treatment and after 4 days of Mg2þ-supple-
mented CPP2 treatment. Protein concentrations of OPN were
increased 4-fold in both CPP2-treated hVSMCs with and
without 2 mmol/L Mg2þ (Figure 2D). SM22a protein expres-
sion showed a non-significant trend towards a reduction in
CPP2-treated cells independent of Mg2þ. MGP protein expres-
sion was stable in all treatment groups. To test whether Mg2þ
might prevent CPP-induced calcification at lower CPP2
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concentrations, Mg2þ was supplemented to VSMCs treated
with a broad range of CPP2 dosages (Figure 3). Both 2 and
5 mmol/L Mg2þ did not reduce VSMC Ca2þ deposition at any
of the CPP2 dosages, ranging from 5 to 100 CPP. Compared
with CPP2 treatment containing no additional Mg2þ, supple-
mentation of 5 mmol/L Mg2þ resulted in increased Ca2þ depo-
sition at 25, 50 and 75 CPP2 [82 6 5% versus 99 6 16% at 75
CPP (P< 0.05), respectively, where 100 CPP2 with no addi-
tional Mg2þ is set to 100% calcification].
Mg2þ dose-dependently prevents secondary CPP
maturation
To study the action of Mg2þ on CPP transition in vitro, CPP
medium was incubated to form CPP1 and CPP2 in the presence
of a range of MgCl2 concentrations. CPP medium showed an
initial increase in absorbance reflecting CPP1 formation after
1 day (absorbance change from 0.042 to 0.055) and the second
increase in absorbance reflecting CPP2 formation after 3 days
(absorbance change from 0.055 to 0.138; Figure 4A). Mg2þ sup-
plementation resulted in a similar increase in absorbance after 1
day of culture (absorbance change of supernatant from 0.042 to
0.057 for 2.0 mmol/L Mg2þ). Mg2þ final concentrations of 1.6,
1.8 and 2.0 mmol/L preserved the CPP1 state for 14 days (final
absorbance 0.077). A final concentration of 1.0, 1.2 and
1.4 mmol/L delayed the second increase in absorbance by 1, 7
and 11 days, respectively. In the presence of 4 and 5 mmol/L Pi,
2 mmol/L Mg2þ inhibited CPP1 to CPP2 transition
(Supplementary data, Figure S1). Increasing Mg2þ to a concen-
tration of 2.0 mmol/L to CPP medium after CPP2 had formed
(on Day 5) did not result in changes in the absorption of the
CPP medium (final absorbance 0.170 versus 0.174). After
14 days, CPP2 and CPP2 supplemented with Mg2þ were iso-
lated and analysed by EM and EDX to study CPP characteristics
(Figure 4B–G). Mg2þ supplementation did not affect the pH of
the CPP mixture (Supplementary data, Figure S2). SEM
revealed similar morphology of the CPP2 independent of Mg2þ
treatment (Figure 4B and E). EDX peaks were present at energy
levels corresponding to enriched Pi and Ca2þ (Figure 4C and
F). Quantification of the peaks showed that Mg2þ-supple-
mented CPP2 contains 37.1% oxygen, 18.7% Pi and 39.4%
Ca2þ, which did not significantly differ from CPP2 without
Mg2þ supplementation (Figure 4D and G). In addition, there
was a slight trend towards increased Naþ, Cl and Mg2þ con-
tent in Mg2þ-supplemented CPP2, but this was not statistically
significant.
FIGURE 1: Mg2þ prevents Pi-induced calcification in hVSMCs. (A) Alizarin red staining was negative in Mg2þ-supplemented Pi cultures, in-
dicating the absence of calcification after 2, 4 and 8 days. (B) Ca2þ deposition on VSMCs was increased in Pi-treated cells compared with con-
trols, but was absent after 2.0 mmol/L Mg2þ supplementation. (C) Pi-induced calcification decreased ALP and non-significantly decreased
calcification inhibitor MGP and VSMC contractile genes SM22a and CNN1 after 6 days (black bars) and 8 days (white bars) of incubation,
which was prevented by Mg2þ. (D) Protein expression of OPN, SM22a and MGP was measured and quantified. Data are shown as fold
changes compared with the day-matched controls and presented as the mean of three separate experiments, consisting of three replicate cul-
tures 6 SD. *P< 0.05 versus day-matched control.
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Mg2þ improves calcification propensity in serum from
CKD patients and healthy controls
To examine the effects of Mg2þ on serum calcification pro-
pensity in CKD patients, the serum of CKD patients and
healthy controls was supplemented with increasing concentra-
tions of Mg2þ ex vivo and subsequently T50 was measured.
Serum Mg2þ concentration was not different between the
groups (0.8 6 0.2 versus 0.9 6 0.5 mmol/L). There was a non-
significant trend towards a lower baseline T50 in CKD patients
compared with controls (372 6 50 versus 323 6 57 min). The
addition of 0.2 mmol/L Mg2þ significantly improved T50 in do-
nor patients by 51 6 16 min and CKD patients by 44 6 13 min
(Figure 5A; P< 0.05). Each increment of 0.2 mmol/L addition
of Mg2þ led to a similar increase of 40 min in CKD patients
and 50 min in healthy controls (Figure 5B).
D I S C U S S I O N
In this study we demonstrate that Mg2þ prevents high Pi–
induced VSMC calcification. The preventive effect of Mg2þ is
mediated via delayed CPP2 formation, because Mg2þ is unable
to prevent calcification once CPP2 has formed. Specifically, we
show that Mg2þ does not prevent CPP1 formation. Rather,
Mg2þ prevents the transition from CPP1 to CPP2. In the sera of
CKD patients and healthy controls, a small increase in Mg2þ of
0.2 mmol/L improved T50, reflecting a decreased calcification
propensity. In addition, our results indicate that crystalline mat-
uration of Pi towards CPP2 is an essential step in VSMC
calcification.
FIGURE 3: High Mg2þ concentration stimulates CPP2-induced cal-
cification. Ca2þ deposition was measured after incubation of VSMCs
for 24 h with varying CPP2 concentrations in the presence of 0.8
(control), 2 and 5 mmol/L Mg2þ. Mg2þ did not prevent CPP2-in-
duced calcification at any CPP concentration. At 5 mmol/L, Mg2þ
increased cellular Ca2þ deposition at CPP2 concentrations of 25, 50
and 75 lg/mL Ca2þ versus CPP2 treatment without additional
Mg2þ. Data are shown as fold changes compared with 100 CPP2 (set
at 100%). Presented data are the mean of three separate experiments
consisting of three replicate cultures 6 SD. P< 0.05 for CPP2 incu-
bated with *0.8, #2 and $5 mmol/L Mg2þ versus CPP2 concentra-
tion-matched formalin-fixed cultures.
FIGURE 2: Mg2þ does not prevent CPP2-induced calcification in hVSMCs. (A) Alizarin red staining and (B) Ca2þ deposition quantification
show that CPP2-induced calcification is not prevented by 2.0 mmol/L Mg2þ after 24 h and 4 days. (C) Gene expression related to calcification
after CPP2 treatment was measured after 2 days (black bars) and 4 days (white bars) and remained unchanged by Mg2þ. (D) Protein expression
of OPN, SM22a and MGP was measured and quantified. Data are shown as fold changes compared with the day-matched controls and pre-
sented as the mean of three separate experiments, consisting of three replicate cultures 6 SD. *P< 0.05.
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FIGURE 4: Mg2þ dose-dependently inhibits the transition from CPP1 to CPP2 and does not affect CPP2 morphology after nucleation. (A)
Absorbance of the CPP mixture containing different Mg2þ concentrations was measured at 570 nm as a readout for CPP1 (0.05 AU) to
CPP2 (0.15 AU) transition. This graph is representative of five independently executed experiments each consisting of three replicates. Data
are expressed as mean 6 SD. A final concentration of 2.0 mmol/L Mg2þ after CPP2 (E–G) formation did not alter morphology (SEM) or com-
position (EDX) compared with control CPP2 (B–D). A TEM picture was inserted in B to confirm CPP2. Scale bars correspond to 300 nm
(white) and 500 nm (black).
FIGURE 5: Mg2þ dose-dependently increases T50 in CKD patient serum. Serum T50 is increased upon Mg
2þ supplementation of serum from
both healthy controls (solid line) and CKD patients (dotted line, A). (B) Change in T50 similar in CKD patients after each addition of Mg
2þ
compared with healthy controls. Black and white bars represent healthy controls and CKD patients, respectively. Data are shown as the mean
of 10 patients in each group and are expressed as mean 6 SD. P < 0.05 *for healthy controls versus baseline; $for CKD patients versus baseline
and #for CKD patients versus healthy controls at specific Mg2þ concentration.
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The mechanism by which Mg2þ prevents high Pi–induced
calcification in CKD models is incompletely understood. Using
different in vitro models, we demonstrate that Mg2þ only pre-
vents Pi-induced VSMC calcification prior to formation of
CPP2. After CPP2 formation, Mg2þ supplementation did not
alter crystal composition and morphology and did not prevent
calcification of VSMCs. In addition, Mg2þ supplementation did
not modify CPP2-induced expression profiles of osteogenic or
VSMC contractility genes and proteins. In contrast, Mg2þ po-
tently prevents Pi-induced calcification through indirect path-
ways, as an increased concentration of Mg2þ was insufficient to
prevent VSMC calcification induced by CPP2. We have shown
previously in a bovine model of VSMC calcification that Mg2þ
blocks Ca2þ-Pi crystal formation preceding Pi-induced calcifi-
cation and independent of transcriptional changes in bovine
VSMCs [19]. Other studies have identified the potent anti-
crystallization properties of Mg2þ [20, 22, 29]. In aqueous solu-
tions, Mg2þ is known to stabilize amorphous Ca2þ-Pi particles
and delay crystal nucleation [30]. Contrarily, another study sug-
gested that the preventive action of Mg2þ on VSMC calcifica-
tion did not depend on the inhibition of CPP2 maturation [31].
For instance, in the study by Louvet et al. [31], hydroxyapatite
crystals were generated in the presence of hVSMC with 1% FBS
only, whereas we used 5% FBS [31]. In low serum
conditions, the availability of calcification inhibitors such as
fetuin-A is lower, resulting in a milieu that is more prone to cal-
cification. Thus the inhibitory effects of Mg2þ on CPP2 forma-
tion may potentially be overruled as Pi can precipitate more
readily [24].
In our study, Mg2þ blocked calcification induced by high Pi,
which is consistent with previous studies [15, 16, 18, 32]. When
comparing our results, it is important to note that the reported
experimental setups have used high Pi to induce VSMC calcifi-
cation and have supplemented Mg2þ immediately in order to
prevent calcification [15, 16, 18, 32]. Under these circumstan-
ces, it is possible that Mg2þ blocked crystal or CPP2 maturation
that would otherwise have occurred naturally. Therefore inhibi-
tion of Pi-induced calcification may have been secondary to the
prevention of CPP2 formation. With high Pi, medium crystals
form spontaneously over time. The cellular effects of CPP2-in-
duced calcification are already present 24 h after induction,
while those of high Pi–induced calcification only occur after1
week. Accordingly, it was shown that crystalline Pi–containing
particles induce calcification and VSMC transdifferentiation
rather than soluble Pi or amorphous Ca2þ-Pi particles (or
CPP1) [6, 8, 11].
Calcification propensity (T50) is a risk factor and indicator
for cardiovascular morbidity and mortality in CKD patients
[23, 33, 34]. To translate the effects of Mg2þ on CPP2 matura-
tion to a more clinical setting, we investigated the effects of
stepwise Mg2þ additions to serum from renal disease patients
and healthy controls on T50. Our results demonstrate that
Mg2þ increased T50 by50 min per 0.2 mmol/L Mg2þ increase
in serum from CKD patients and healthy controls. Interestingly,
the dose-dependent effects of Mg2þ on calcification propensity
are similar in both groups. These ex vivo results are consistent
with a previous study in patients on dialysis [35, 36]. It was
demonstrated that Mg2þ effectively and promptly increased T50
by 72 min once dialysate Mg2þ was adjusted from 0.5 to
1.0 mmol/L, which resulted in a serum increase of 0.36 mmol/L
[36]. Dialysate Mg2þ supplementation increased T50 without
modifying intracellular Mg2þ concentrations, consistent with
the notion that serum Mg2þ is key to modify calcification pro-
pensity [36]. The ability of Mg2þ to potently modify T50 is of
great clinical interest. Given the sensitivity of T50 for Mg
2þ, this
relationship should be clinically exploited. Further clinical stud-
ies should investigate whether ex vivo determinations of calcifi-
cation propensity could be used to define optimal dialysate or
oral Mg2þ concentration for CKD patients.
Our results indicate that cellular Pi toxicity leading to calcifi-
cation is determined by the presence of crystalline Pi in the
form of CPP2. Efforts to prevent vascular calcification are cur-
rently aimed at lowering serum Pi concentrations in CKD
patients. Importantly, management of serum Pi by Pi binders is
insufficient to decrease the risk for cardiovascular disease and
vascular calcification in CKD [37]. Instead, determinants affect-
ing the transition from Pi towards crystalline Pi (CPP2) poten-
tially prove to be more clinically relevant. Mg2þ prevented
VSMC calcification in vitro despite high Pi concentrations and
improved calcification propensity in humans without normaliz-
ing serum Pi concentrations [19, 36]. In addition, increased se-
rum Mg2þ (>1.27 mmol/L) neutralizes the association between
serum Pi concentration and the risk for cardiovascular mortal-
ity [38]. Therefore Mg2þ potentially disarms Pi toxicity in CKD
without changing the soluble Pi concentration itself. As such, Pi
toxicity, and therefore calcification risk, should be clinically de-
termined based on Pi crystallinity.
This is the first study that uses CPP2-induced VSMC calcifi-
cation to distinguish intracellular effects from extracellular
effects of Mg2þ. In addition, our approach includes in vitro
models and an ex vivo study coupling the effects of Mg2þ to cal-
cification propensity. Although we demonstrate that Mg2þ lim-
its VSMC calcification primarily through the inhibition of
CPP2 maturation already at small incremental concentrations,
we cannot exclude potential contributing effects of intracellular
pathways related to calcification. While the results presented
here need to be verified in vivo, our conclusions may have im-
portant implications for clinical interpretation of the effects of
Mg2þ on calcification. Recently a longer-term randomized clin-
ical study using oral magnesium oxide supplements showed
halted progression of coronary artery calcification in pre-
dialysis CKD patients [39]. Another study is currently being ini-
tiated (ClinicalTrials.gov identifier NCT02542319) [40]. These
studies are a major step towards improving cardiovascular out-
comes in CKD patients using Mg2þ supplements.
In conclusion, our study demonstrates that Mg2þ prevents
hVSMC calcification by inhibition of CPP2 maturation
in vitro. In serum from CKD patients, Mg2þ increased T50 in a
dose-dependent manner. Increasing serum Mg2þ may be a
promising treatment to target pathological CPP2 maturation in
CKD-induced vascular calcification.
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